Delta-9-Tetrahydrocannabinol (THC) Protects Partly against Demyelination by Modulating the Inflammatory Response: An In Vitro Study in Aggregating Brain Cell Cultures

Antoinette Defaux1, Mariano Schiffrin1, Lorianne Vorlet-Fawer1, Amelie Speihmann1, Christian Giroud1,2 and Florianne Monnet-Tschudi1,2*

1Department of Physiology, University of Lausanne, CH-1005 Lausanne, Switzerland
2SCAHT (Swiss Centre for Applied Human Toxicology)
3Laboratory of Forensic Toxicology and Chemistry, University Center of Legal Medicine, Lausanne-Geneva, and University Hospital Center and University of Lausanne, Switzerland

Abstract

Delta 9-tetrahydrocannabinol (THC) has been proposed as therapeutic agent in the treatment of multiple sclerosis. In the present study, we examined whether a modulation of brain inflammation by THC may protect against demyelination. Myelinating aggregating brain cell cultures were subjected to demyelination by a repeated treatment (3x) with the two inflammatory agents interferon-γ (IFN-γ) and lipopolysaccharide (LPS). The effects of THC on an acute inflammatory response were also examined by treating the aggregates with a single application of the two inflammatory agents. THC effects on the demyelinating process and on several mediators of the inflammatory response were analyzed.

THC treatment partially prevented the decreased immunoreactivity for MBP, and the decrease in MBP content measured by immunoblotting. It prevented IFN-γ + LPS-induced microglial reactivity; and decreased the IFN-γ + LPS-induced increased phosphorylation of p44/42 MAP kinase. The other inflammatory markers, i-NOS and TNF-α mRNA expression, and p38 MAP kinase phosphorylation were downregulated by THC treatment following a single application of the inflammatory agents, but not after repeated applications.

THC protected partially against the IFN-γ + LPS-induced demyelination. The protective effect of THC on IFN-γ + LPS-induced demyelination may be due to a decrease of the inflammatory response. However, the anti-inflammatory effect of THC on some inflammatory markers is lost when the inflammatory response is more prominent and of longer duration, suggesting either that the anti-inflammatory effect of a molecule may depend on the properties of the inflammatory response, or that the anti-inflammatory potential of THC decreases in case of repeated exposure.

Keywords: Demyelination; Neuroinflammation; Microglia; Cytokines; THC; MAP kinases

Introduction

Delta-9-tetrahydrocannabinol (THC) is the main psychoactive compound of cannabis. Cannabinoids have been proposed as therapeutic drugs in multiple sclerosis (MS) for both the control of spasticity and the modulation of brain inflammation [1-7]. THC interacts mainly with two receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) [8-11] CB2 was first identified in immune cells [12]. In brain, the expression of CB2 by microglial cells [13] is upregulated when they are activated [14]. Recent studies show that glial cells also express cannabinoids-like receptors, which seems to be involved in the regulation of immune functions (for review, [15]). The Peroxisome Proliferator-Activated Receptors (PPARs) can be activated by cannabinoids [16] and may mediate some of their anti-inflammatory effects (for review, [17]). Ajulemic acid, an analog of a metabolite of THC binds to PPAR-α [18], and endocannabinoids were shown to be natural activators of PPAR-α and PPAR-γ [16].

The anti-inflammatory potential of THC, as well as of endogenous and synthetic agonists of the various cannabinoid receptors has been widely reported. THC can block NO liberation in LPS-stimulated macrophages [19]. Faccinetti and collaborators [20] have shown that endogenous and synthetic cannabinoids prevent TNF-α release by LPS-stimulated microglia. In astrocytes, endogenous cannabinoids have been shown to inhibit NO and TNF-α production induced by LPS [21,22]. Furthermore, cannabinoids can induce the expression of anti-inflammatory cytokines such as IL-4 and IL-10 [23]. They can inhibit neurodegeneration in models of multiple sclerosis [24]. In experimental autoimmune encephalomyelitis (EAE), an animal model of MS, attenuation of the interactions between immune cells and endothelial cells by cannabinoids may be neuroprotective [25]. It has been proposed that CB2 receptor played a key role in attenuating EAE progression through modulation of the immune response [26]. Activation of the endocannabinoid system was shown to be beneficial in a chronic mice model of MS, reducing neuroinflammation, excitoxicity and motor disability [27-29].

In the present work, serum-free aggregating brain cell cultures [30] were used as model to study the effects of THC on brain inflammation, and demyelination. In these three-dimensional cell cultures, all brain cell types (i.e., neurons, astrocytes, oligodendrocytes, and microglia) are present in proportions close to the situation in vivo, and organized in a histotypic manner. During 3-4 weeks in vitro, a...
sequence of morphogenetic events occurs, including the formation of compact myelin around axons [31]. It is important to note that this in vitro model is devoid of lymphocytes and allows to study the role of neuroinflammation in the demyelinating and remyelinating processes in the absence of the peripheral inflammatory cells.

Previous work [32] showed that in mature aggregating brain cell cultures, the combined treatment with interferon-γ (IFN-γ) and lipopolysaccharide (LPS), two inflammatory agents, induced microglial activation and the upregulation of a variety of inflammatory mediators including cytokines and chemokines. This inflammatory response was accompanied by demyelination in the absence of neuronal damage or cell death. In the present work, making use of this experimental paradigm, it was found that THC prevented the microglial activation triggered by the combined treatment with IFN-γ and LPS, and partially protected against the concomitant demyelination. This protective effect may be due to a decrease of the inflammatory response. In order to further study the anti-inflammatory potential of THC, the mRNA expression of i-NOS, TNF-α and IL-1β, as well as the phosphorylation state of p44/42 and p38 MAP kinases were measured after a single and a repeated (3x) treatment with the two inflammatory agents. In addition, the involvement of PPAR-γ in the anti-inflammatory effects of THC was examined by using an antagonist of PPAR-γ and by measuring the mRNA expression of PPAR-γ.

Materials and Methods

Aggregating brain cell cultures

Serum-free aggregating brain cell cultures were prepared from the telencephalon of 16-day embryonic rats (Hsd:SD, Harlan, NL-5960 AD Horst) as described previously in detail [30,33]. The embryonic brain tissue was mechanically dissociated using nylon sieves of 200-µm and 100-µm pores, and the dissociated cells were incubated under gyratory agitation in serum-free medium. The resulting aggregate cultures were maintained in serum-free medium (DMEM adjusted for serum-free conditions) under constant gyratory agitation (80 rpm) at 37°C in an atmosphere of 10% CO₂ and 90% humidified air. Media were replenished by the replacement of 5 ml of culture supernatant (of a total of 8 ml per flask) with fresh medium every 3rd day until day in vitro (DIV) 14, and every 2nd day thereafter. For experimentation, replicate cultures were prepared by randomizing and aliquoting the free-floating aggregates of the original cultures. For media replenishment in replicate cultures, aliquots of 2.5 ml spent medium were replaced by fresh medium.

Combined treatment with IFN-γ and LPS

A single treatment with IFN-γ (50 U/ml final concentration) and LPS (5 µg/ml final concentration) was applied to investigate the effect of an acute inflammatory response. A prolonged inflammatory response and the accompanying demyelination were triggered by the repeated treatment with IFN-γ (50 U/ml final concentration) and LPS (5 µg/ml final concentration). The treatment, initiated at DIV 22, was repeated twice, at DIV 24 and DIV 26 (last treatment), each time after media replenishment. Stock solutions were prepared, for IFN-γ (Peprotec) in phosphate buffered saline (PBS) containing 0.1 % bovine serum albumin (pH 8), and for LPS (Sigma) in 0.9% NaCl.

THC and GW9662 treatments

Stock solutions of (-)-Δ⁹-Tetrahydrocannabinol (THC) at a concentration of 1.0 mg/ml ethanol were purchased from Lipomed AG, Arlesheim, Switzerland. THC final concentration was chosen according to Monnet-Tschudi et al. [34]. THC (1 µM final concentration) was given simultaneously with the inflammatory agents IFN-γ and LPS, from a 10³-fold concentrated stock solution prepared in Ethanol. GW9662 (2-Chloro-5-nitro-phenylbenzamide) was obtained from Tocris bioscience, Lucerna chem. AG., Lucerne, Switzerland. GW9662 (2 µM final concentration, chosen according to Zurich et al. [35]) was applied alone or together with THC 1 hour before the inflammatory agents from a 10³-fold concentrated stock solution prepared in Ethanol.

Western blot analysis

Cultures were washed twice with PBS at 4°C. Western Blot analysis were done according to previous publications [32,36]. Aggregates were homogenized in lysis buffer (10 mM Tris-HCl ph 7.5, 6M Urea, 0.1% SDS, 1/100 Complete protease inhibitor, and 1/100 sodium-orthovanadate). The protein content was measured by the BCA assay. Per well, 40 to 60 µg of protein was loaded. Blots were stripped (Re-Blot Plus Mild antibody stripping solution; Chemicon) and incubated with antibody against β actin (1/30000; Sigma) to demonstrate equal loading of protein in each lane. The autoradiograms were scanned and processed by image analysis (Quantity One, BioRad). Data were acquired in arbitrary densitometric units and transformed to percentages of densitometric levels obtained from scans of control samples visualized on the same blot.

Quantitative RT-PCR

Aggregating brain cell cultures were washed twice with 5 ml of ice-cold PBS, and the pellet stored at -80°C. The RNase kit from Qiagen was used to extract total RNA. The reverse transcription (RT) reaction was performed using the High capacity cDNA Reverse Transcription Kit and protocols from Applied Biosystem (ABI, Foster City, CA, USA). Briefly, the RT was run with 2 µg of total RNA in a reaction volume of 20 µl. Aliquots of this reaction mixture were used for the subsequent PCR reactions. The expression of iNOS was quantified using SYBR Green (ABI), whereas the expression of IL-1β, IL-6 and TNF-α was quantified using Taqman gene expression assay (ABI) as previously published [32,35].

Immunocytochemical and Isolectin B4 stainings

Aggregating brain cell cultures were washed twice with pre-warmed PBS, embedded in cryomatrix (Jung, Nussloch, Germany), frozen in isopentane cooled with liquid nitrogen, and stored at -80°C. For immunocytochemistry, cryosections (10 µm) were fixed for 15 minutes in 4% paraformaldehyde dissolved in PBS at room temperature, and then washed in PBS. For blockade of non-specific binding, sections were first incubated in normal horse serum (1/25 in PBS with 0.1% Triton-X100, Jackson) and exposed overnight at 4°C to antibodies against MBP (mouse monoclonal, 1/40, Chemicon). Sections were then incubated with the horse anti-mouse biotinylated IgG (1/200, Vector) and mounted in ProLong Gold antifade reagent (Invitrogen). For the staining of microglia by the specific binding of FITC-conjugated isolectin B4 of Griffonia simplicifolia (IB4), cryosections were washed for 15 minutes in Tris buffer containing 1% Triton X-100 and then incubated for 30 minutes in Image-IT FX signal enhancer (Invitrogen). Sections were then exposed overnight at 4°C to IB4 (1/500, Sigma). Image J software was used to quantify the labeled area of aggregate sections. Sections from the central area of aggregates were taken for analysis. Threshold of fluorescence was defined and set up in some images of the control untreated cultures in order to cover all labeled area above background, and was applied to all images of the different treatments. Only changes in labelled area are reported here. Results are expressed as percentage of untreated control cultures.
Statistics

Data are expressed as mean ± standard error of the mean (SEM). For western blot analysis, data are expressed as percentages of untreated control cultures and each value is the average of 8-9 replicate cultures obtained in 3 independent experiments, using cultures of different batches. Data were statistically evaluated for significance by the Kruskal-Wallis test followed by the Mann-Whitney test using Stata software. For quantitative RT-PCR, data are expressed as fold changes of untreated control cultures, and each value is the average of 6-8 replicate cultures of 3-4 independent experiments. Data were also statistically evaluated for significance by the Kruskal-Wallis test followed by the Mann-Whitney test. For immunostaining, data are expressed as percentages of untreated control cultures, and each value is the average of the quantification of 20 aggregate images from one experiment. The analysis of 3 independent experiments produced similar results. Data were statistically evaluated by one-way ANOVA followed by the Tukey post-test.

Results

Aggregating brain cell cultures were treated from DIV 22 to DIV 26 with the two inflammatory agents, IFN-γ (50 U/ml) and LPS (5 μg/ml). THC (1 μM) was given simultaneously with the administration of the two inflammatory agents. The effects of THC on demyelination were assessed by measuring MBP expression and content by immunocytochemistry and immunoblotting, respectively.

Cultures treated with IFN-γ and LPS exhibited strongly decreased MBP immunostaining (Figure 1 C vs A, and E) indicating that demyelination occurred. THC together with the inflammatory agents partially prevented the decreased immunoreactivity for MBP (Figure 1, D vs. C, and E). In the absence of the inflammatory stimulation, THC did not modify the immunoreactivity for MBP (Figure 1 B vs A). These findings were confirmed by western blot analysis for MBP (Figure 2). Treatment with the demyelinating agents strongly reduced MBP content (Figure 2 A and B) and the addition of THC partially prevented the decrease in MBP content (Figure 2 A and C). In the absence of the inflammatory stimulation, THC did not alter the MBP content (Figure 2). These observations taken together indicate that THC partially prevented the demyelination triggered by the inflammatory agents.

To investigate how THC can protect against demyelination, its effects on the inflammatory response induced by IFN-γ and LPS were examined. The extent of the inflammatory reactions was evaluated taking as criteria IB4 staining, and the expression of i-NOS, TNF-α and IL-1β. To investigate the effects of THC on the mRNA expression of the inflammatory mediators, THC was applied simultaneously with the repeated treatment with IFN-γ and LPS (3X) and also with a single treatment with the inflammatory agents.

The results (Figure 3) show that the combined treatment with the two inflammatory agents significantly increased IB4 staining (Figure 3), indicating microglial activation as previously described [37,38]. Addition of THC reduced the IB4 staining to the level of untreated cultures (Figure 3), indicating that THC prevented the activation of microglial cells by the pro-inflammatory treatment. In the absence of the inflammatory stimulus, THC did not affect IB4 staining (Figure 3).

A single and a repeated application of the inflammatory agents strongly upregulated the mRNA expression of i-NOS (Figure 4A), TNF-α (Figure 4B), and IL-1β (Figure 4C). I-NOS and TNF-α expression, were more upregulated after the repeated treatment (Figure 4A and B, black bars vs white bars), whereas IL-1β expression was more upregulated after the single treatment (Figure 4C, black bars vs white bars). When cultures were treated only once, the addition of THC significantly decreased the upregulation of i-NOS and tended to reduced TNF-α expression (Figure 4A and B, white bars), whereas it did not affect significantly IL-1β increased expression (Figure 4 C, white bars). When the treatments were repeated, THC did not decrease i-NOS, TNF-α and IL-1β upregulated expression (Figure 4, black bars). In the absence of the inflammatory stimulus, THC did not affect i-NOS, TNF-α and IL-1β expression (Figure 4).

To further investigate the modulation of the inflammatory cascade, changes in the phosphorylation of p44/42 (Erk1/2) and p38 MAP kinases were examined by western blot analysis. The results (Figure 5) show that the treatment of cultures with the two inflammatory agents given either once or three times significantly increased the phosphorylation of p44/42 MAP kinase (Figure 5A, B, D) and of p38 MAP kinase (Figure

![Figure 1: Effects of THC on MBP immunostaining.](image-url)

Aggregate cultures remained either untreated (A), or were treated with THC (1 μM) (B); IFN-γ (50 U/ml) plus LPS (5 μg/ml) (C); or treated with THC simultaneously with the inflammatory agents (D). Cultures were harvested 48 hours after the last treatment with the inflammatory agents. The MBP staining was quantified (E), measuring 20 aggregate sections per treatment and expressing the stained area as percent of untreated control cultures. The Figure shows representative data from one experiment. Results were statistically evaluated for significance by one-way ANOVA test followed by the Tukey post-test. (T vs Ctrl: *P<0.05, ***P<0.001, compared with untreated control cultures. **P<0.05, ***P<0.001, compared with cultures treated with the inflammatory agents). Bar = 100μm.

GW9662 applied simultaneously with THC did not block the THC-induced decrease in i-NOS mRNA expression observed after the single application of IFN-γ + LPS. Even, when applied alone, it decreased the IFN-γ + LPS-induced upregulation of i-NOS mRNA after the single treatment with the inflammatory agents and lost this effect after the repeated treatment (Figure 6A). Similar observations were made for TNF-α (not shown). To further investigate the role of PPAR-γ in the THC-induced modulation of the inflammatory response, the mRNA expression of PPAR-γ was measured. It was found that IFN-γ + LPS tended to decrease PPAR-γ mRNA expression and that THC and GW9662 applied alone did not modify this response (Figure 6B). When THC and GW9662 were applied together, PPAR-γ mRNA expression returned to control level after the acute treatment with the inflammatory agents (Figure 6B). No modification of PPAR-γ mRNA expression by THC and GW9662 applied alone or together were observed after the repeated treatment with the inflammatory agents (Figure 6B).

Discussion

In multiple sclerosis, beneficial effect of cannabinoids on symptomatic spasms and pain have been evidenced by several clinical trials [39-41]. Whether disability progression can be slowed by cannabinoid treatments remained to be demonstrated [41]. Experimental studies aim at studying the mechanisms underlying the efficacy of cannabinoids treatments. In the present study we showed that THC partially protects against INF-γ and LPS-induced demyelination. We have then investigated whether this protective effect was mediated by a modulation of the neuroinflammatory response.

As expected, IFN-γ + LPS-induced microglial reactivity was downregulated by THC. But THC decreased the mRNA expression of i-NOS and TNF-α only after the single treatment with the inflammatory agents, but not after the repeated one. Regarding the MAP kinase pathways, that are involved in the inflammatory response [42], the increased phosphorylation of p44/42 was attenuated by THC and GW9662 applied alone or together were observed after the repeated treatment with the inflammatory agents (Figure 6B).

In order to examine whether an activation of cannabinoid-like receptors and in particular of PPAR-γ may be involved in the anti-inflammatory effect of THC observed in the acute neuroinflammation, the irreversible PPAR-γ antagonist GW9662 (2 μM) was applied alone or together with THC 1 hour before the inflammatory agents.
phosphorylation was decreased only after the single application of IFN-γ + LPS. P38 MAP kinase is implicated in the signal transduction pathway responsible for the increased expression of i-NOS and TNF-α [43,44]. Therefore, the decrease in i-NOS and TNF-α expression induced by THC could be related to the decreased activation of p38. Although p44/42 signaling plays also a role in i-NOS expression in microglia [43-45], it appears that after a repeated treatment with the inflammatory agents, the attenuation of p44/42 phosphorylation by THC was not sufficient to modulate i-NOS expression. The lack of effect of THC on i-NOS and TNF-α expression and on p38 activation after the repeated exposure to the inflammatory agents could be due to the repeated application of THC leading to an

Figure 4: Effects of THC on iNOS (A), TNF-α (B) and IL-1β (C) mRNA expression.
Aggregate cultures remained either untreated [Ctrl] or were treated with THC (1 µM) [T]; IFN-γ (50 U/ml) plus LPS (5 µg/ml) [I+L]; or treated with THC simultaneously with the inflammatory agents [I+L+T]. These treatments were applied one time (1X) or three times (3X). Panel A shows representative western blots for phosphorylated-p44/42 [P-p44/42], phosphorylated-p38 [P-p38], and actin. Panels B, D, and F show quantification of phosphorylated-p44, phosphorylated-p42 and p38, respectively, expressed as percentage of untreated control cultures (=100%). Panels C, E, and G show quantification of phosphorylated-p44, p42 and p38, respectively, expressed as percentage of cultures treated with the inflammatory agents (=100%). Cultures were harvested 24 hours after the treatments. Measuring β-actin expression assessed equal loading of protein. Each value is the mean of 8 - 9 replicate cultures. Results were statistically evaluated for significance by the Kruskal-Wallis test followed by the Mann-Whitney test. (*P<0.05, **P< 0.01, ***P<0.001 compared with untreated control cultures; °P<0.05, °°P< 0.01 compared with cultures treated with the inflammatory agents.

Figure 5: Effects of THC on p44/42 and p38 phosphorylation.
Aggregate cultures remained either untreated [Ctrl] or were treated with THC (1 µM) [T]; IFN-γ (50 U/ml) plus LPS (5 µg/ml) [I+L]; or treated with THC simultaneously with the inflammatory agents [I+L+T]. These treatments were applied one time (1X) or three times (3X). Panel A shows representative western blots for phosphorylated-p44/42 [P-p44/42], phosphorylated-p38 [P-p38], and actin. Panels B, D, and F show quantification of phosphorylated-p44, phosphorylated-p42 and p38, respectively, expressed as percentage of untreated control cultures (=100%). Panels C, E, and G show quantification of phosphorylated-p44, p42 and p38, respectively, expressed as percentage of cultures treated with the inflammatory agents (=100%). Cultures were harvested 24 hours after the treatments. Measuring β-actin expression assessed equal loading of protein. Each value is the mean of 8 - 9 replicate cultures. Results were statistically evaluated for significance by the Kruskal-Wallis test followed by the Mann-Whitney test. (*P<0.05, **P< 0.01, ***P<0.001 compared with untreated control cultures; °P<0.05, °°P< 0.01 compared with cultures treated with the inflammatory agents. The lack of effect of THC on i-NOS and TNF-α expression and on p38 activation after the repeated exposure to the inflammatory agents could be due to the repeated application of THC leading to an
Internalization of cannabinoid receptors [46,47]. A single application of THC given with the last (third) treatment with the inflammatory agents tended to downregulate IL1β mRNA expression (data not shown), suggesting that the anti-inflammatory effects of THC can also be mediated by CB-like receptors, mainly those related to high concentrations of THC (1 µM) [15], such as used in this study. While THC at very high concentration (5 µM) induced a upregulation of PPAR-γ mRNA expression (data not shown), the concentration used here did not modify PPAR-γ mRNA expression neither in the resting conditions, nor after IFN-γ + LPS treatments. Treatments with the inflammatory agents decreased PPAR-γ mRNA expression, as previously described in microglial cells and astrocytes [49,50]. To further test the involvement of PPAR-γ in the anti-inflammatory effect of THC, we examined whether the non-reversible antagonist of PPAR-γ, GW9662, could block the THC-induced decrease of i-NOS expression in the acute inflammatory response. GW9662 not only did not block the anti-inflammatory effect of THC, but even behaved similarly than THC, it decreased i-NOS and TNF-α mRNA expression in case of the single treatment with IFN-γ + LPS, and lost this effect in case of the repeated treatment. Paradoxical anti-inflammatory effect of GW9662 has been observed in a monocytic cell line [51]. The authors discussed these paradoxical results by suggesting that GW9662 could also function as a partial agonist for PPAR-α, that was reported to be also anti-inflammatory [52,53]; or that the effects of GW9662 may be mediated through mechanisms other than the canonical pathway of PPAR-γ activation. When the PPAR-γ antagonist and THC were applied together, the expression of PPAR-γ mRNA returned to control levels in case of the single treatment with IFN-γ + LPS, suggesting synergic effects of PPAR-γ antagonist and THC.

The differential effects of THC and GW9662 in the acute versus the prolonged inflammatory responses triggered by a single or a repeated treatment with IFN-γ + LPS, respectively, could signify that the characteristics of neuroinflammation change with time. In line with this hypothesis is the paper of Janabi and coworkers [54], that showed that acute and prolonged stimulation of microglia and astrocytes with IFN-γ, IL-1β and TNF-α caused differential expression of several IFN-γ, IL-1β and TNF-α caused differential expression of several anti-inflammatory effect, did not protect against antibody-mediated demyelination [38]. And an agonist of PPAR-β, that showed a clear anti-inflammatory effect, did not protect against antibody-mediated demyelination [56]. Taken together, these results emphasize the central potential of THC. However, the protection against demyelination appeared to be due to the anti-inflammatory potential of THC. However, the protection against demyelination appeared very variable. Previous studies have shown that minocycline, an antibiotic known to decrease microglial reactivity [55] did not protect against demyelination, but favour remyelination [38]. And an agonist of PPAR-β, that showed a clear anti-inflammatory effect, did not protect against antibody-mediated demyelination [56]. Taken together, these results emphasize the central potential of THC.

The consequences of an anti-inflammatory treatment on a demyelinating insult appeared very variable. Previous studies have shown that minocycline, an antibiotic known to decrease microglial reactivity [55] did not protect against demyelination, but favour remyelination [38]. And an agonist of PPAR-β, that showed a clear anti-inflammatory effect, did not protect against antibody-mediated demyelination [56]. Taken together, these results emphasize the central potential of THC. However, the protection against demyelination appeared very variable. Previous studies have shown that minocycline, an antibiotic known to decrease microglial reactivity [55] did not protect against demyelination, but favour remyelination [38]. And an agonist of PPAR-β, that showed a clear anti-inflammatory effect, did not protect against antibody-mediated demyelination [56]. Taken together, these results emphasize the central potential of THC.
role of neuroinflammation in the demyelinating and remyelinating processes, but also the difficulty to predict the beneficial effects of an anti-inflammatory treatment in therapeutic interventions.

Beside the ability to decrease neuroinflammation, cannabinoid-induced immunosuppression may also be associated with a reduction of T cells responsiveness or with an increased myeloid progenitor trafficking towards the inflammed foci (for review, [57]). For a therapeutic application, it remained to be demonstrated whether a protective or reductive effect of THC is achieved when applied after the demyelinating insult or continuously as a preventive treatment. However, long term treatments with relatively high concentrations was shown to induce neurotoxic effects [34], limiting a long term therapeutic use of THC.

Acknowledgements

The excellent technical assistance of Ms Brigitte Delacuisine and Denise Tavel is greatly acknowledged. This work was supported by a grant of the Swiss Society for Multiple Sclerosis to F.M.T.

References


This article was originally published in a special issue, *Neuropharmacology & Neurotoxicity* handled by Editor(s): Dr. Terreia S Jones, University of Tennessee Health Science Center, USA